Myovant Sciences Ltd. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 40 rows in 2020. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2020-12-28: Reporting owner KARBE FRANK; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2020-12-18: Reporting owner Arjona Ferreira Juan Camilo; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2020-12-18: Reporting owner Lang Matthew; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2020-12-15: Reporting owner Arjona Ferreira Juan Camilo; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2020-12-28 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −11,800 183,544 owned after | $5.11 exercise price | 2020-12-30 | |
| 2020-12-18 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,000 191,267 owned after | $7.78 exercise price | 2020-12-22 | |
| 2020-12-18 | Lang Matthew Officer (General Counsel & Corp. Secy.) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 250,000 owned after | $7.78 exercise price | 2020-12-22 | |
| 2020-12-15 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,000 193,267 owned after | $7.78 exercise price | 2020-12-17 | |
| 2020-12-15 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,050 195,344 owned after | $5.11 exercise price | 2020-12-17 | |
| 2020-12-10 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 200,267 owned after | $7.78 exercise price | 2020-12-14 | |
| 2020-12-10 | Lang Matthew Officer (General Counsel & Corp. Secy.) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −19,400 260,000 owned after | $7.78 exercise price | 2020-12-11 | |
| 2020-12-09 | Lang Matthew Officer (General Counsel & Corp. Secy.) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −600 279,400 owned after | $7.78 exercise price | 2020-12-11 | |
| 2020-11-30 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 196,394 owned after | $5.11 exercise price | 2020-12-02 | |
| 2020-11-17 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −750 197,894 owned after | $5.11 exercise price | 2020-11-19 | |
| 2020-11-17 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,000 210,267 owned after | $7.78 exercise price | 2020-11-19 | |
| 2020-11-13 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −750 198,644 owned after | $5.11 exercise price | 2020-11-17 | |
| 2020-11-13 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,000 217,267 owned after | $7.78 exercise price | 2020-11-17 | |
| 2020-09-15 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −750 199,394 owned after | $5.11 exercise price | 2020-09-17 | |
| 2020-09-15 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,000 224,267 owned after | $7.78 exercise price | 2020-09-17 | |
| 2020-09-15 | Curran Terrie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +21,603 21,603 owned after | $21.47 exercise price | 2020-09-17 | |
| 2020-09-15 | GUINAN MARK Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +21,603 21,603 owned after | $21.47 exercise price | 2020-09-17 | |
| 2020-09-15 | Gulfo Adele M. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +21,603 21,603 owned after | $21.47 exercise price | 2020-09-17 | |
| 2020-09-15 | POTTER MYRTLE S Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +21,603 21,603 owned after | $21.47 exercise price | 2020-09-17 | |
| 2020-09-15 | Sebelius Kathleen Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +21,603 21,603 owned after | $21.47 exercise price | 2020-09-17 | |
| 2020-08-31 | Lang Matthew Officer (General Counsel & Corp. Secy.) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −26,700 280,000 owned after | $7.78 exercise price | 2020-09-02 | |
| 2020-08-31 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −11,307 231,267 owned after | $7.78 exercise price | 2020-09-02 | |
| 2020-08-31 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −21,150 200,144 owned after | $5.11 exercise price | 2020-09-01 | |
| 2020-08-28 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,650 221,294 owned after | $5.11 exercise price | 2020-09-01 | |
| 2020-08-28 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −267 65,863 owned after | $7.78 exercise price | 2020-08-31 | |
| 2020-08-28 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,791 242,574 owned after | $7.78 exercise price | 2020-08-31 | |
| 2020-08-28 | Lang Matthew Officer (General Counsel & Corp. Secy.) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,600 306,700 owned after | $7.78 exercise price | 2020-08-28 | |
| 2020-08-26 | Lang Matthew Officer (General Counsel & Corp. Secy.) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −100 309,300 owned after | $7.78 exercise price | 2020-08-28 | |
| 2020-08-19 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −700 224,944 owned after | $5.11 exercise price | 2020-08-21 | |
| 2020-08-19 | Lang Matthew Officer (General Counsel & Corp. Secy.) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −600 309,400 owned after | $7.78 exercise price | 2020-08-21 | |
| 2020-08-19 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −635 244,365 owned after | $7.78 exercise price | 2020-08-21 | |
| 2020-06-24 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,946 245,000 owned after | $7.78 exercise price | 2020-06-26 | |
| 2020-06-24 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,500 80,550 owned after | $7.78 exercise price | 2020-06-26 | |
| 2020-06-23 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,054 255,946 owned after | $7.78 exercise price | 2020-06-24 | |
| 2020-04-03 | Seely Lynn Director, Officer (Principal Executive Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +302,693 302,693 owned after | $8.08 exercise price | 2020-04-07 | |
| 2020-04-03 | Sablich Kim Officer (Chief Commercial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +134,464 134,464 owned after | $8.08 exercise price | 2020-04-07 | |
| 2020-04-03 | Lang Matthew Officer (General Counsel & Corp. Secy.) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +170,396 170,396 owned after | $8.08 exercise price | 2020-04-07 | |
| 2020-04-03 | KARBE FRANK Officer (Principal Fin'l & Accounting) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +183,991 183,991 owned after | $8.08 exercise price | 2020-04-07 | |
| 2020-04-03 | Arjona Ferreira Juan Camilo Officer (Chief Medical Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +134,464 134,464 owned after | $8.08 exercise price | 2020-04-07 | |
| 2020-02-24 | Gulfo Adele M. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +45,000 45,000 owned after | $11.17 exercise price | 2020-02-24 |